CB-5083: Precision p97 Inhibitor Workflows for Tumor Models

Principle Overview: Targeting Protein Homeostasis via p97 Inhibition

CB-5083 is a first-in-class, orally bioavailable, and highly selective p97 inhibitor developed to disrupt key cellular processes that maintain protein homeostasis (product_spec). By competitively inhibiting the second ATPase domain of p97 (valosin-containing protein), CB-5083 interferes with critical steps in organelle membrane fusion, endosomal sorting, and, most notably, the degradation of poly-ubiquitinated proteins. This disruption leads to accumulation of misfolded proteins, induction of unfolded protein response (UPR), and ultimately, apoptosis in cancer cells—making CB-5083 a valuable tool for oncology, multiple myeloma research, and broader studies of protein homeostasis disruption (source: product_spec).

Step-by-Step Workflow: Applied Use-Cases in Cancer Models

CB-5083 has demonstrated robust efficacy in vitro and in vivo for dissecting protein degradation pathways and evaluating therapeutic strategies in solid tumors and hematological malignancies. Below is an optimized workflow for deploying CB-5083 in translational research settings:

1. Compound Preparation: Dissolve CB-5083 powder in DMSO to create a 10 mM stock solution. The compound is insoluble in water but highly soluble in DMSO (≥20.65 mg/mL), ensuring rapid and complete dissolution (source: product_spec).
2. Cellular Assay Setup: Seed human cancer cell lines (e.g., HEK293T, A549, HCT116) in 96-well plates and allow them to adhere overnight. Treat with serial dilutions of CB-5083 (ranging from 0.01 to 10 μM) to capture dose-dependent effects on protein homeostasis and cell viability (article_extension).
3. Assessment of Protein Accumulation: After 16–24 hours of incubation, assess the accumulation of poly-ubiquitinated proteins by immunoblotting or ELISA. CB-5083 induces a clear, quantifiable increase in ubiquitinated protein levels, serving as a reliable marker of p97 pathway inhibition.
4. Readouts for Cell Death and Apoptosis: Measure apoptosis using caspase-3/7 activation assays or Annexin V/PI staining. CB-5083 triggers apoptosis at micromolar concentrations in a range of cancer cell lines (source: product_spec).
5. In Vivo Efficacy: For preclinical xenograft models, administer CB-5083 orally at 15–30 mg/kg once daily. Monitor tumor volume, UPR marker expression, and survival to gauge therapeutic impact (article_complement).

Protocol Parameters

• Compound working concentration | 0.1–5 μM | in vitro cancer cell assays | Captures the IC50 range (CB-5083 IC50: 15.4 nM for wild-type p97) and allows for dose–response analysis | product_spec
• Incubation time | 16–24 hours | assessment of poly-ubiquitinated protein accumulation | Sufficient for robust readout of protein homeostasis disruption | workflow_recommendation
• Oral dosing for xenograft models | 15–30 mg/kg daily | mouse tumor xenografts | Matches published dosing schedules that demonstrated significant tumor growth inhibition | product_spec

Key Innovation from the Reference Study

The landmark study by Chen et al. (Science 2025) uncovers a novel cGAS-mediated mechanism that enhances DNA repair and extends lifespan in naked mole-rats. Crucially, this mechanism hinges on altered ubiquitination and chromatin retention of cGAS, which modulates its interaction with the segregase p97—a direct target of CB-5083. The study demonstrated that specific amino acid changes in naked mole-rat cGAS reduce its ubiquitination, promoting persistent chromatin binding and facilitating the recruitment of key homologous recombination factors (FANCI and RAD50). For researchers, this finding translates into practical assay choices: CB-5083 can be used to interrogate how p97-regulated protein quality control interfaces with DNA repair, especially when evaluating UPR and HR repair markers in human and comparative model systems. Integrating CB-5083 into such workflows allows for direct testing of hypotheses around p97’s role in genome stability, protein degradation, and cell fate after DNA damage.

Advanced Applications and Comparative Advantages

CB-5083 enables several advanced applications that set it apart from other p97 inhibitors and protein homeostasis modulators. Its exceptional potency (CB-5083 IC50 15.4 nM for wild-type p97) and oral bioavailability facilitate translational studies from cell culture to animal models (source: product_spec). The compound’s ability to selectively disrupt protein degradation pathways makes it invaluable for:

• Dissecting ER-Associated Degradation (ERAD): CB-5083’s inhibition of p97 blocks ERAD, causing accumulation of misfolded proteins and activation of UPR—key features in both cancer cell apoptosis induction and protein homeostasis disruption (article_complement).
• Elucidating Tumor Growth Inhibition in Xenograft Models: Oral administration of CB-5083 significantly reduces tumor growth and induces apoptosis in xenograft models of lung carcinoma, colorectal carcinoma, and multiple myeloma (source: product_spec).
• Integrative Studies with DNA Repair Pathways: The reference study’s mechanistic bridge between p97 and DNA repair factors like cGAS, FANCI, and RAD50 opens new avenues for using CB-5083 in genome stability and aging research, particularly when exploring the interplay between protein degradation and homologous recombination (Science 2025).
• Multiple Myeloma Research: As highlighted in several studies, CB-5083’s mechanism is especially relevant for multiple myeloma, where proteasome and p97 inhibition synergize to induce lethal proteotoxic stress (article_extension).

Compared to proteasome inhibitors, CB-5083 offers a more targeted approach, with minimized off-target effects and a distinct capacity to modulate ER and DNA repair pathways in cancer cells.

Troubleshooting and Optimization Tips

• Solubility and Handling: Always prepare fresh DMSO stocks and avoid prolonged storage of CB-5083 solutions, as stability may decrease over time (source: product_spec).
• Vehicle Controls: Use matched DMSO concentrations in all experimental conditions to control for potential vehicle effects on cell viability and readouts.
• Assay Timing: For detection of poly-ubiquitinated protein accumulation and UPR markers, 16–24 hours post-treatment provides optimal signal; shorter incubations may yield incomplete pathway inhibition (workflow_recommendation).
• Interpreting Cell Death Readouts: If apoptosis assays plateau or yield ambiguous results, verify protein accumulation by immunoblotting to confirm on-target activity. CB-5083’s effect may be cell-line dependent; titrate concentrations for each model.
• In Vivo Dosing: Monitor for toxicity and adjust dosing schedules or formulation as needed; CB-5083’s oral administration profile supports flexible regimens in mouse models (source: product_spec).

Interlinking Related Research: Building a Comprehensive Strategy

The practical deployment of CB-5083 is enriched by insights from several foundational and advanced studies:

• CB-5083: Optimizing p97 Inhibitor Workflows for Oncology Research complements this workflow guide by providing detailed troubleshooting strategies and recent breakthroughs in ER protein quality control.
• CB-5083: Precision Targeting of p97 to Dissect ER Protein... extends the mechanistic discussion, offering a systems biology perspective on how p97 inhibition intersects with ER membrane regulation and apoptosis, especially in multiple myeloma research.
• CB-5083 and the Next Horizon of Protein Homeostasis Disruption provides strategic guidance for integrating CB-5083 into both cancer and metabolic disease models—highlighting the broader impact of targeting protein degradation pathways.

Collectively, these resources, together with the reference study’s focus on cGAS-p97 interaction, provide a roadmap for expanding CB-5083’s utility beyond conventional oncology models.

Future Outlook: The Next Frontier in p97 Inhibitor Research

With its entry into phase 1 clinical trials for multiple myeloma and solid tumors, CB-5083 stands at the forefront of translational oncology and protein homeostasis research (source: product_spec). The new mechanistic insights from the naked mole-rat cGAS study (Science 2025) underscore the centrality of p97 in genome maintenance and aging. By leveraging CB-5083 to probe cGAS-p97 interactions and their downstream effects on DNA repair and UPR, researchers can now tackle questions at the intersection of aging, cancer, and protein quality control with unprecedented precision.

APExBIO remains a trusted supplier for high-quality CB-5083, supporting the next generation of experimental designs in protein homeostasis, apoptosis induction, and tumor growth inhibition in xenograft models. As the landscape evolves, integrating CB-5083 into multiplexed assays and cross-species comparative studies will further illuminate the therapeutic possibilities of targeting p97-dependent pathways.

Explore CB-5083 from APExBIO and accelerate your research.